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The catalog of cancer driver mutations in protein-coding genes has greatly expanded in the
past decade. However, non-coding cancer driver mutations are less well-characterized and
only a handful of recurrent non-coding mutations, most notably TERT promoter mutations,
have been reported. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Gen-
omes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658
cancer across 38 tumor types, we perform multi-faceted pathway and network analyses of
non-coding mutations across 2583 whole cancer genomes from 27 tumor types compiled by
the ICGC/TCGA PCAWG project that was motivated by the success of pathway and network
analyses in prioritizing rare mutations in protein-coding genes. While few non-coding
genomic elements are recurrently mutated in this cohort, we identify 93 genes harboring
non-coding mutations that cluster into several modules of interacting proteins. Among these
are promoter mutations associated with reduced mRNA expression in TP53, TLE4, and TCF4.
We ﬁnd that biological processes had variable proportions of coding and non-coding
mutations, with chromatin remodeling and proliferation pathways altered primarily by coding
mutations, while developmental pathways, including Wnt and Notch, altered by both coding
and non-coding mutations. RNA splicing is primarily altered by non-coding mutations in this
cohort, and samples containing non-coding mutations in well-known RNA splicing factors
exhibit similar gene expression signatures as samples with coding mutations in these genes.
These analyses contribute a new repertoire of possible cancer genes and mechanisms that
are altered by non-coding mutations and offer insights into additional cancer vulnerabilities
that can be investigated for potential therapeutic treatments.
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Over the past decade, cancer genome sequencing effortssuch as The Cancer Genome Atlas (TCGA) have iden-tiﬁed millions of somatic aberrations; however, the
annotation and interpretation of these aberrations remain a major
challenge1. Speciﬁcally, while some somatic aberrations occur
frequently in speciﬁc cancer types, there is a “long tail” of rare
aberrations that are difﬁcult to distinguish from random pas-
senger aberrations in modestly sized patient cohorts2,3. In many
cancers, a signiﬁcant proportion of patients do not have known
driver mutations in protein-coding regions4, suggesting that
additional driver mutations remain undiscovered. The vast
majority of known driver mutations affect protein-coding
regions. Only a few recurrent non-coding driver mutations,
most notably mutations in the TERT promoter5,6, have been
identiﬁed. In other studies, a genome-wide analysis has identiﬁed
recurrent mutations in several regulatory elements, and expres-
sion quantitative trait loci (eQTLs) analysis has identiﬁed non-
coding somatic mutations that correlate with gene expression
changes in some cancer types7.
Cancer driver mutations unlock oncogenic properties of cells
by altering the activity of hallmark pathways8. Accordingly,
cancer genes have been shown to cluster in a small number of
cellular pathways and interacting subnetworks3,9. Consequently,
pathway and network analysis has proven useful for implicating
infrequently mutated genes as cancer genes based on their
pathway membership and physical or regulatory interactions with
recurrently mutated genes10–14. However, the interactions
between coding and non-coding driver mutations in known or
novel pathways have not yet been systematically explored.
As part of the Pan-Cancer Analysis of Whole Genomes
(PCAWG) project of the International Cancer Genome Con-
sortium (ICGC)15, we performed pathway and network analysis
of coding and non-coding somatic mutations from 2583 tumors
from 27 tumor types. The PCAWG consortium curated whole-
genome sequencing data from a total of 2658 cancers across
38 tumor types. In the marker paper15, this work provided the
largest collection of uniformly processed cancer whole genomes
to date with germline and somatic variants from reanalyzed
sequencing data aligned to the human genome (reference build
hs37d5) using standardized and highly accurate pipelines. Recent
work from the PCAWG project of the ICGC reveals few recurrent
non-coding drivers in analyses of individual genes and regulatory
regions16. Here, we employ seven distinct pathways and network
analysis methods and derive consensus sets of pathway-implicated
driver (PID) genes from the predictions of these methods. Spe-
ciﬁcally, we identify a consensus set of 93 high-conﬁdence
pathway-implicated driver genes using non-coding variants (PID-
N) and a consensus set of 87 pathway-implicated driver genes
using coding variants (PID-C). Both sets of PID genes, particu-
larly the PID-N set, contain rarely mutated genes that interact
with well-known cancer genes, but were not identiﬁed as sig-
niﬁcantly mutated by single gene tests16. In total, 121 novel PID-
N and PID-C genes are revealed as promising candidates,
expanding the landscape of driver mutations in cancer.
We examined the relative contributions of coding and non-
coding mutations in altering biological processes, ﬁnding that
while chromatin remodeling and some well-known signaling and
proliferation pathways are altered primarily by coding mutations,
other important cancer pathways, including developmental
pathways, such as Wnt and Notch, are altered by both coding and
non-coding mutations in PID genes. Intriguingly, we ﬁnd many
non-coding mutations in PID-N genes with roles in RNA spli-
cing, and samples with these non-coding mutations exhibit
similar gene expression signatures as samples with well-known
coding mutations in RNA splicing factors. Our analysis demon-
strates that somatic non-coding mutations in untranslated and in
cis regulatory regions constitute a complementary set of genetic
perturbations with respect to coding mutations, affect several
biological pathways and molecular interaction networks, and
should be further investigated for their role in the onset and
progression of cancer.
Results
The long tail of coding and non-coding driver mutations. We
analyzed the genes targeted by single-nucleotide variants (SNVs)
and short insertions and deletions (indels) identiﬁed by whole-
genome sequencing in the 2538 ICGC PCAWG tumor samples
from 27 tumor types. Our pathway and network analyses focused
on a subset of 2252 tumors that excluded melanomas and lym-
phomas due to their atypical distributions of mutations in reg-
ulatory regions17. We utilized the pan-cancer driver p-values of
single protein-coding and non-coding elements from the
PCAWG Drivers and Functional Interpretation Working
Group analysis16, including exons, promoters, untranslated
regions (5′ UTR and 3′ UTR), and enhancers. This analysis
integrates predictions from 16 driver discovery methods, resulting
in consensus driver p-values for coding and non-coding elements;
see ref. 16 for further details. The p-values of individual genes and
non-coding elements indicate their statistical signiﬁcance as dri-
vers, according to diverse methods that account for positive
selection, functional impact of mutations, regional mutation rates,
and mutational processes and signatures16. Among protein-
coding driver p-values of the pan-cancer cohort, 75 genes were
statistically signiﬁcant (FDR < 0.1; Supplementary Fig. 1) and an
additional 7 genes were observed at near-signiﬁcant levels (0.1 ≤
FDR < 0.25). These numbers are consistent with previous reports
of a “long tail” of driver genes with few highly mutated genes and
many genes with infrequent mutations across cancer types2,18.
Non-coding mutations exhibit a similar long-tail distribution
with even fewer signiﬁcant genes (eight genes at FDR < 0.1
and two genes at 0.1 ≤ FDR < 0.25). No single gene has both
signiﬁcant or near-signiﬁcant coding and non-coding driver
p-values (FDR < 0.25), suggesting that non-coding mutations
target a complementary set of genes as coding mutations.
Earlier studies have demonstrated that proteins harboring
coding driver mutations interact with each other in molecular
pathways and networks signiﬁcantly more frequently than
expected by chance2,3,9–11,13. We observed signiﬁcant numbers
of interactions between both signiﬁcantly mutated coding and/or
non-coding elements, suggesting that the pathway and network
methods may be useful in prioritizing rare driver events that are
not signiﬁcant by single-element analyses (Supplementary Fig. 2;
Coding and non-coding mutations cluster on networks in
Supplementary ﬁle).
Pathway and network analysis of potential driver mutations.
We performed a comprehensive pathway and network analysis of
cancer drivers using the single-element driver p-values computed
by the PCAWG Drivers and Functional Interpretation Working
Group16 as input. We applied seven distinct pathways and net-
work methods (ActivePathways19, CanIsoNet20, Hierarchical
HotNet21, a hypergeometric analysis (Vazquez), an induced
subnetwork analysis (Reyna and Raphael, in preparation),
NBDI22, and SSA-ME23) that each leverage information from
molecular pathways or protein interaction networks (Fig. 1,
Methods section) to amplify weak signals in the single-element
analysis. All methods were calibrated on randomized data
(Pathway and network methods in Supplementary ﬁle).
Since the prioritization of non-coding somatic mutations in
cancer is not yet a solved problem, it was difﬁcult to know in
advance which analysis methodologies, if any, would be best
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suited to distinguish drivers from passengers by aggregating
weak signals across pathways or networks. Thus, we formed a
consensus of multiple methods, following the “wisdom of
crowds” ensemble approach of machine learning24 to improve
the speciﬁcity of the results. We included methods that used
different sources of pathway or network information and
different prioritization criteria (see Supplementary Data 1 for a
complete list). Each method nominated genes, and consensus sets
of genes with possible coding and non-coding driver mutations
were deﬁned as the genes found by at least four of the seven
methods (Supplementary Data 2–5). We use the term pathway-
implicated driver (PID) genes to describe these candidate
driver genes.
One potential concern with a consensus procedure is that the
results may be dominated by a few highly correlated methods.
Our pathway or network analysis methods use varied sources of
prior knowledge (i.e., pathway databases or interaction networks),
and input data (e.g., driver p-values, point mutations, and/or gene
expression), and rely on different techniques to integrate these
data sources. We found only a modest overlap between the output
of the seven methods (Method results comparison and Consensus
procedure in Supplementary ﬁle; Supplementary Data 6–8),
suggesting a non-uniform weighting of the consensus to mitigate
the inﬂuence of redundant methods was not necessary.
Using coding mutations alone, we identify a set of 87 pathway-
implicated driver genes with coding variants (PID-C genes). The
87 PID-C genes (Supplementary Data 2, Supplementary Fig. 6a)
include 68 previously identiﬁed cancer genes as catalogued by the
COSMIC Cancer Gene Census (CGC) database (v83, 699 genes
from Tier 1 and Tier 2)25 (2.98 genes expected; Fisher′s exact test
p= 3.57 × 10−83; Fig. 2a, c; Supplementary Fig. 7a). The PID-C
genes have signiﬁcantly higher coding gene scores than non-PID-
C genes (rank-sum test p= 1.72 × 10−58; median rank 48 of PID-
C genes), and each of the 87 PID-C genes improves the score of
its network neighborhood (19.7 genes expected; p < 10−6;
Supplementary Data 9). This network neighborhood analysis
shows that PID-C genes are not implicated solely by their
network neighbors14, but themselves contribute signiﬁcantly
to their discovery by the pathway and network methods. The
87 PID-C genes also include 31 genes that are not statistically
signiﬁcant (FDR > 0.1) in the PCAWG Drivers and Functional
Interpretation Working Group analysis; Fig. 2a, c; Supplementary
Figs. 8a, 9), illustrating that the network neighborhoods can
nominate genes with infrequent mutations, i.e., those in the “long
tail”, as possible driver genes. Interestingly, 13 of these 31 genes
with FDR > 0.1 are also known drivers according to the CGC
database (3.0 genes expected; Fisher’s exact test p= 2.1 × 10−14).
Thus, the consensus pathway and network analysis recovers many
known protein-coding driver mutations and identiﬁes additional
possible drivers that are infrequently mutated and thus remain
below the statistical signiﬁcance threshold of gene-speciﬁc driver
analyses.
Using non-coding mutations alone, we identify a set of
62 genes using our consensus pathway and network analysis,
resulting in fewer genes than our analysis with coding mutations.
However, when we performed a joint analysis of coding and
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Fig. 1 Overview of the pathway and network analysis approach. Coding, non-coding, and combined gene scores were derived for each gene by aggregating
driver p-values from the PCAWG driver predictions in individual elements, including annotated coding and non-coding elements (promoter, 5′ UTR, 3′ UTR, and
enhancer). These gene scores were input to ﬁve network analysis algorithms (CanIsoNet20, Hierarchical HotNet21, an induced subnetwork analysis (Reyna and
Raphael, in preparation), NBDI22, and SSA-ME23), which utilize multiple protein–protein interaction networks, and to two pathway analysis algorithms
(ActivePathways19 and a hypergeometric analysis (Vazquez)), which utilize multiple pathway/gene-set databases. We deﬁned a non-coding value-added
(NCVA) procedure to determine genes whose non-coding scores contribute signiﬁcantly to the results of the combined coding and non-coding analysis, where
NCVA results for a method augment its results on non-coding data. We deﬁned a consensus procedure to combine signiﬁcant pathways and networks
identiﬁed by these seven algorithms. The 87 pathway-implicated driver genes with coding variants (PID-C) are the set of genes reported by a majority (≥4/7)
of methods on the coding data. The 93 pathway-implicated driver genes with non-coding variants (PID-N) are the set of genes reported by a majority of
methods on non-coding data or in their NCVA results. Only ﬁve genes (CTNNB1, DDX3X, SF3B1, TGFBR2, and TP53) are both PID-C and PID-N genes.
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non-coding mutations, we found that the much stronger signal in
coding mutations dominated the combined signal in coding and
non-coding mutations. To increase sensitivity to detect contribu-
tions of non-coding mutations, we devised a “non-coding
value-added” (NCVA) procedure (Fig. 1; Supplementary Fig. 3;
Non-coding value-added (NCVA) procedure in the Methods
section). Our NCVA procedure asks if the coding mutations
enhance the discovery of potential non-coding driver genes
beyond what is found with only the non-coding mutations. This
procedure identiﬁed an additional set of 31 genes that, when
merged with the 62 genes found with non-coding mutations
alone, resulted in a set of 93 pathway-implicated driver genes with
non-coding variants (PID-N) (Supplementary Fig. 4, Consensus
results in the Methods section). PID-N genes appear as a robust
and biologically relevant set, unbiased by any particular
mutational process reﬂecting a particular carcinogen or DNA
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Fig. 2 Pathway and driver analysis identiﬁes driver genes in the long tail of the driver p-values for coding and non-coding mutations. a Pathway and
network methods identify signiﬁcant coding driver mutations. Driver p-values on protein-coding elements for 250 genes with most signiﬁcant coding driver
p-values; dashed and dotted lines indicate FDR= 0.1 and 0.25, respectively. Dark green bars are PID-C genes, and light green bars are non-PID-C genes.
Blue squares below the x-axis indicate COSMIC Cancer Gene (CGC) Census genes. In total, 31 of 87 PID-C genes have coding driver p-values with FDR >
0.1. Several PID-C genes are labeled, including all CGC genes with coding FDR > 0.1. Overlap between PID-C and PID-N genes is indicated with asterisks.
Source data are provided as a Source Data ﬁle. b Pathway and network methods identify rare non-coding driver mutations. Driver p-values on non-coding
elements (promoter, 5′ UTR, and 3′ UTR of gene) for 250 genes with most signiﬁcant non-coding driver p-values; dashed and dotted lines indicate FDR=
0.1 and 0.25, respectively. Dark yellow bars are PID-N genes, and light yellow bars are non-PID-N genes. Blue squares are as above. In total, 3 (TERT, HES1,
and TOB1) of 93 PID-N genes have non-coding driver p-values with FDR ≤ 0.1, while 90 have FDR > 0.1 . Several PID-N genes are labeled, including PID-N
genes with signiﬁcant in cis gene expression changes (see Fig. 3) and all PID-N genes with non-coding FDR > 0.25. Overlap between PID-C and PID-N
genes is indicated with asterisks. Source data are provided as a Source Data ﬁle. c Statistical signiﬁcance of overlap between top-ranked genes according to
coding driver p-values and PID-C genes with CGC genes. Fisher’s exact test p-values and driver FDR thresholds of 0.1 and 0.25 are highlighted. Green
squares indicate overlap between PID-C genes and CGC genes. Source data are provided as a Source Data ﬁle. d Statistical signiﬁcance of overlap of genes
ranked by driver p-values on non-coding (promoter, 5′ UTR, 3′ UTR) elements and CGC genes. Driver FDR thresholds of 0.1 and 0.25 are highlighted.
Yellow square indicates overlap between PID-N genes and CGC genes. Source data are provided as a Source Data ﬁle.
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damage processes (Supplementary Fig. 5, Mutational signatures
in the Methods section).
The 93 PID-N genes (Supplementary Data 3, Supplementary
Fig. 6b) include 19 previously identiﬁed cancer genes according to
the COSMIC Cancer Gene Census (CGC) database a signiﬁcant
enrichment over the 3.2 genes expected (p= 5.3 × 10−11;
Fisher’s exact test, Fig. 2b, d; Supplementary Figs. 7b, c).
Excluding the eight genes with individually signiﬁcant non-
coding elements in the PCAWG Drivers and Functional
Interpretation Working Group analysis16, 19 genes are both
PID-N genes and CGC genes, a signiﬁcant enrichment over the
3.1 genes expected (p= 5.3 × 10−11; Fisher’s exact test), suggest-
ing that non-coding mutations may alter genes with recurrent
coding or structural variants in some samples. The PID-N genes
have signiﬁcantly higher non-coding gene scores than non-PID-
N genes (rank-sum test p= 1.47 × 10−58; median rank 165 of
PID-N genes), and 92/93 PID-N genes (except for HIST1H2BO)
improve the scores of their network neighborhoods (28.5 genes
expected; p < 10−6; Supplementary Data 10). This shows that
PID-N genes are not implicated solely by their network
neighbors14. The vast majority of PID-N genes (90/93, including
the 19 CGC genes) are distinct from the PCAWG Drivers and
Functional Interpretation Working Group analysis (Fig. 2b;
Supplementary Figs. 8b, 9), with only three genes in common:
TERT, HES1, and TOB1. Of these three, only TERT is recorded as
a known cancer gene in the CGC database. Moreover, the 93 PID-
N genes are more strongly enriched (p= 5.3 × 10−11; Fisher’s
exact test) for COSMIC CGC genes than the 93 genes with the
smallest non-coding driver p-values of promoters, 5′ UTRs, or
3′ UTRs (p= 4.8 × 10−3; Fisher’s exact test). Thus, our consensus
procedure of the pathway and network analyses appreciably
augments the signiﬁcantly mutated elements in the PCAWG
Drivers and Functional Interpretation Working Group results16.
Taken together, the PID-C and PID-N genes contain an
additional 121 genes over what was found in the PCAWG Drivers
and Functional Interpretation Working Group analysis, including
90 new possible non-coding drivers (Consensus Results in the
Methods section). In total, non-coding mutations in PID-N genes
cover an additional 151 samples (9.1% of samples) than PID-C
genes. We found that most coding mutations in PID-C genes and
most non-coding mutations in PID-N genes are clonal (median >
80% for both PID-C and PID-N genes26). In addition, the
overwhelming majority of the PID-N genes were distinct from
PID-C genes (Supplementary Fig. 4) with only ﬁve genes in
common: CTNNB1, DDX3X, SF3B1, TGFBR2, and TP53. While
this suggests that coding and non-coding driver mutations occur
in largely distinct sets of cancer genes, we show below that both
types of mutations affect genes underlying many of the same
hallmark cancer processes.
Impact of non-coding mutations on gene expression. Non-
coding mutations may act by altering transcription factor-binding
sites or other types of regulatory sites. Thus, we evaluated whether
non-coding mutations in PID-N genes were associated with in cis
expression changes in the same gene. We found that ﬁve PID-N
genes (FDR < 0.3) showed signiﬁcant in cis expression correla-
tions out of the 90 that could be tested using RNA-Seq data
(Fig. 3; Supplementary Fig. 10; Supplementary Data 11–16).
In contrast, 34 out of 87 PID-C genes exhibited signiﬁcant or
near-signiﬁcant in cis expression correlations (FDR < 0.3)
(Supplementary Data 17, 18).
Unsurprisingly, the most signiﬁcant in cis expression correla-
tion for a PID-N gene is the correlation between TERT promoter
mutations and increased expression, which we ﬁnd in 11 Thy-
AdenoCA tumors (p= 1.3 × 10−10, FDR= 3.2 × 10−9; Wilcoxon
rank-sum test), 11 CNS-Oligo tumors (p= 6.8 × 10−3, FDR=
9.7 × 10−2; Wilcoxon rank-sum test), and 22 CNS-GBM tumors
(Wilcoxon rank-sum test p= 2.3 × 10−2, FDR= 0.19; Wilcoxon
rank-sum test) (Supplementary Fig. 8), consistent with previous
reports5,6,27. Note that these associations were limited by the
unavailability of RNA expression data for some samples with
TERT mutations as well as the low-sequencing coverage in
promoter regions that limited the detection of TERT promoter
mutations. The PCAWG Drivers and Functional Interpretation
Working Group investigated the latter issue for two mutation
hotspot sites in the TERT promoter, and estimated that 216
mutations in these sites were likely not called16, a large
underrepresentation relative to the total of 97 samples with
TERT promoter mutations (71 samples with expression data) in
our analyses.
We found signiﬁcant in cis expression correlations in four
other PID-N genes: TP53, TLE4, TCF4, and DUSP22 (Fig. 3,
Supplementary Fig. 10). TP53 shows signiﬁcantly reduced
expression (p= 1.0 × 10−3; FDR= 8.7 × 10−2; Wilcoxon rank-
sum test) across six tumors with TP53 promoter mutations from
six different tumor types (Fig. 3a; Supplementary Fig. 10). The
reduced expression of mutated samples is consistent with TP53’s
well-known role as a tumor suppressor gene, and links between
TP53 promoter methylation and expression have been previously
investigated28. This expression change was also described in the
study by the PCAWG Drivers and Functional Interpretation
Working Group16. TLE4 shows signiﬁcantly reduced expression
(p= 1.7 × 10−2; FDR= 0.20; Wilcoxon rank-sum test) in three
Liver-HCC tumors with TLE4 promoter mutations (Fig. 3b;
Supplementary Fig. 10). TLE4 is a transcriptional co-repressor
that binds to several transcription factors29, and TLE4 functions
as a tumor suppressor gene in acute myeloid lymphoma through
its interactions with Wnt signaling30. Furthermore, in an acute
myeloid lymphoma cell line, TLE4 knockdown increased cell
division rates, while forced TLE4 expression induced apoptosis31.
However, the role of TLE4 in solid tumors is not well understood.
TCF4 shows signiﬁcantly reduced expression (p= 3.4 × 10−2;
FDR= 0.27; Wilcoxon rank-sum test) in three Lung-SCC tumors
with TCF4 promoter mutations (Fig. 3c; Supplementary Fig. 10).
TCF4 is part of the TCF4/β-catenin complex and encodes a
transcription factor that is downstream of the Wnt signaling
pathway. Low TCF4 expression has been observed in Lung-SCC
tumors32. Finally, DUSP22 has signiﬁcantly reduced expressed
(p= 6.3 × 10−3; FDR= 0.024; Wilcoxon rank-sum test) in ﬁve
Lung-AdenoCA patients with DUSP22 3′ UTR mutations
and signiﬁcantly over-expressed (p= 7.8 × 10−4; FDR= 0.075;
Wilcoxon rank-sum test) in three Lung-AdenoCA patients with
DUSP22 5′ UTR mutations. These UTR mutations were mutually
exclusive. DUSP22 encodes a phosphatase signaling protein, and
was recently proposed to be a tumor suppressor in lymphoma33.
While these gene expression correlations provide additional
support for a subset of PID-N genes, the variant allele frequency
of a mutation and the copy number of the gene are additional
covariates for gene expression. We found that these covariates did
not play a role in of the correlations that we identiﬁed: the
majority of mutations in each PID gene were clonal (Supple-
mentary Fig. 11) and copy-number changes did not affect the
expression correlations for the ﬁve PID-N genes described above
(Fig. 3; Supplementary Fig. 10). In addition, the low number of
PID-N genes exhibiting associated gene expression changes is
explained by the low number of samples with mutations in PID-
N genes, the uneven availability of expression data across the
tumor types, and decreased sequence coverage in promoter
regions16. These issues further reduced the number of samples
with non-coding mutations and RNA expression, limiting the
power of in cis gene expression correlation analysis.
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Modular organization of coding and non-coding mutations.
We identiﬁed speciﬁc protein–protein interaction subnetworks
and biological pathways that were altered by coding mutations,
non-coding mutations, or a combination of both types of
mutations. We found signiﬁcantly more interactions between
PID-C genes that expected by chance using a node-degree pre-
serving permutation test (64 interactions observed vs. 40 inter-
actions expected, p < 10−6), a near-signiﬁcant number of
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interactions between PID-N genes (18 vs. 12 expected, p= 6.8 ×
10−2), and signiﬁcantly more interactions between both PID-C
and PID-N genes (67 vs. 40 expected, p= 6 × 10−4), demon-
strating an interplay between coding and non-coding mutations
on physical protein–protein interaction networks (Network
annotation in the Methods section). We organized the interacting
subnetworks involving PID-C and PID-N genes into ﬁve biolo-
gical processes: core drivers, chromatin organization, cell pro-
liferation, development, and RNA splicing (Fig. 4a). While the
high frequency of molecular interactions between PID-C and
PID-N genes is expected since such interactions were used as a
signal in pathway and network methods, the organization of these
interactions illustrates the relative contributions of coding and
non-coding mutations in individual subnetworks.
We further characterized the molecular pathways enriched
among our PID-C and PID-N using the g:Proﬁler web server34
(Fig. 4b; Supplementary Fig. 12, Supplementary Data 19–24,
Pathway annotation in the Methods section). Overall, 63 pathways
were enriched for PID-C genes and 13 pathways were enriched for
PID-N genes (FDR < 10−6). Since our gene-prioritization methods
use pathway databases and interaction networks as prior knowl-
edge, it is not surprising that PID-C and PID-N genes are enriched
in multiple molecular pathways. However, the enrichment results
provide clues about the modular organization of the pathways and
allow us to assess the relative contributions of coding and non-
coding mutations in each pathway.
We further grouped these molecular pathways into 29 modules
using overlaps between annotated pathways recorded in the
pathway enrichment map (Supplementary Fig. 12). For each
enriched module, we examined whether PID-C, PID-N, or both
types of genes were responsible for the observed enrichment. This
produced a clustering of modules and PID genes into four
biological processes: chromatin organization, cell proliferation,
development, and RNA splicing (Fig. 4b).
We found that pathways in the chromatin and cell proliferation
processes—including chromatin remodeling and organization,
histone modiﬁcation, apoptotic signaling, signal transduction, Ras
signaling, and cell growth—were altered primarily by coding
mutations in PID-C genes. This is not surprising as these pathways
contain many well-known cancer genes, such as TP53, KRAS,
BRAF, cyclin-dependent kinase inhibitors, EGFR, PTEN, and RB1.
At the same time, we found that multiple signaling pathways
include signiﬁcant numbers of both PID-C and PID-N genes,
suggesting that non-coding mutations provide an alternative to
coding mutations in disrupting these pathways. In particular, the
Wnt signaling pathway (FDR= 6.8 × 10−13), which was pre-
dominantly targeted by coding mutations, was also targeted by
non-coding mutations in several PID-N genes, including TERT
(103 mutations), HNF1A/B (24 mutations), TLE4 (32 mutations),
TCF4 (93 mutations), and CTNNB1 (17 mutations) (Supplemen-
tary Fig. 13a). The Notch signaling pathway (FDR= 6.8 × 10−7)
was associated with comparable numbers of PID-C and PID-N
genes, including the PID-N genes JAG1 and MIB1 that encode
ligands and the PID-N transcription factors ACL1, HES1, and
HNF1B (66 non-coding mutations in total) (Supplementary
Fig. 13b). The TGF-β signaling pathway (FDR= 3.2 × 10−7) also
contained both PID-C and PID-N genes, including the PID-N
genes HES1, HNF1A/B, HSPA5, MEF2C, and the genes
TGFBR2 and CTNNB1, which are both PID-C and PID-N genes
(214 coding mutations and 166 non-coding mutations).
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We found that several developmental processes were altered by
signiﬁcant numbers of both PID-C and PID-N genes. Cell fate
determination (FDR= 2.0 × 10−7) was predominantly affected by
non-coding mutations in the PID-N genes DUSP6,MEF2C, JAG1,
SOX2, HES1, ACL1, ID2, SUFU, and KLF4 (total 191 non-coding
mutations), but also by coding mutations in PID-C genes BRAF,
GATA3, and NOTCH1/2. Pathways related to nervous system
development (FDR= 5.8 × 10−8) were enriched for the PID-N
genes ASCL1, CTNNB1, ID2, SUFU, and TERT that have known
roles in cancer35,36, complementing the PID-C genes NOTCH1,
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PTEN, and RHOA that also have known cancer roles. The pattern
speciﬁcation process (FDR= 8.8 × 10−8) was also affected by
both coding and non-coding mutations, including the PID-N
genes ASCL1, SUFU, and RELN and the PID-C genes ATM and
SMAD4. In these cases, non-coding mutations complement the
coding mutations that disrupt these pathways, covering addi-
tional patients.
Intriguingly, we ﬁnd that RNA splicing pathways were affected
primarily by non-coding mutations (FDR= 7.6 × 10−9). A total of
17 PID-N genes involved in splicing-related pathways (Supple-
mentary Fig. 13c), including several heterogeneous nuclear
ribonucleoproteins (hnNRP) and serine- and arginine-rich splicing
factors (SRSFs). None of these PID-N genes were signiﬁcantly
mutated according to single-element tests used in the PCAWG
Drivers and Functional Interpretation Working Group analysis16.
As we did not ﬁnd any signiﬁcant (FDR < 0.1) in cis
associations between non-coding mutations and altered expres-
sion in splicing-related PID-N genes, we explored potential in
trans effects between non-coding mutations in these genes and
expression of other genes. We found that non-coding mutations in
splicing-related PID-N genes largely recapitulate a recently
published association from a TCGA PanCanAtlas analysis37
between coding mutations in several splicing factors and
differential expression of 47 pathways (Fig. 5). In particular, we
identiﬁed three clusters of mutations in RNA splicing genes (C1,
C2, and C3; Fig. 5a, b) using hierarchical clustering of differential
expression patterns across these pathways. A highly overlapping
set of clusters was found using t-distributed stochastic neighbor
embedding (top annotation bar in Fig. 5a) showing that the
clusters were robust to the choice of the clustering method.
Further support for robustness of clusters was found via silhouette
scores and bootstrapping (Supplementary Fig. 14). Each of these
clusters contained at least one coding mutation in the splicing
genes SF3B1, FUBP1, and RBM10, as reported previously37, along
with non-coding mutations in splicing-related PID-N genes,
demonstrating that both types of mutations resulted in similar
gene expression signatures. The joint analysis of coding and non-
coding mutations in splicing factors also recovered the two groups
of enriched pathways37 (P1 and P2 in Fig. 5a; Supplementary
Fig. 15). One group (P1) is characterized by immune cell
signatures and the other group (P2) reﬂects mostly cell-
autonomous gene signatures of cell cycle, DDR, and essential
cellular machineries37. This similarity between the gene expression
signatures for non-coding mutations in several PID-N splicing
factors and the signatures previously reported for coding
mutations in splicing factor genes37 supports a functional role
for splicing-related PID-N genes in altering similar gene
expression programs.
In addition to the above modules, we also found that
transcription factors were well represented among both the
PID-C and PID-N genes. In total, nine PID-C genes are
transcription factors (ARHGAP35, ARID2, FOXA1, GATA3,
NFE2L2, SMAD4, SOX9, TCF7L2, TP53; FDR= 2.1 × 10−10),
while 19 PID-N genes are transcription factors (ASCL1,
BHLHE40, ESRRG, HES1, HNF1A, HNF1B, HOXA10, HOXB5,
KLF4, MEF2C, MYC, NFE2, NR2F1, SOX2, SOX4, TCF4, TP53,
ZNF521, ZNF595; FDR= 4.1 × 10−20). This observation suggests
that non-coding mutations may affect transcriptional regulatory
networks.
Discussion
We present an integrative pathway and network analysis that
expands the list of genes with possible non-coding driver muta-
tions into the “long tail” of rarely mutated elements that are not
signiﬁcant by single-element analysis. We ﬁnd that genes har-
boring both coding or non-coding mutations overlap in pathways
and networks; thus, pathway databases and interaction networks
serve as useful sources of prior knowledge to implicate additional
mutated elements beyond those identiﬁed by single-element tests.
In total, our integrative pathway and network analysis identiﬁed
87 pathway-implicated driver genes with coding variants (PID-C)
and 93 pathway-implicated driver genes with non-coding variants
(PID-N). Importantly, 90 PID-N genes were not statistically
signiﬁcant (FDR > 0.1) by single-element tests on non-coding
mutation data, and these genes are key candidates for future
experimental characterization. Among them, we ﬁnd that pro-
moter mutations in TP53, TLE4, and TCF4 are associated with
reduced expression of these genes.
We ﬁnd that coding and non-coding driver mutations largely
target different genes and make varying contributions to path-
ways and networks perturbed in cancer. While some cancer
pathways are targeted by both coding and non-coding mutations,
such as the Wnt and Notch signaling pathways, other pathways
appear to be predominantly altered by one class of mutations.
In particular, we ﬁnd non-coding mutations in multiple genes in
the RNA splicing pathway, and samples with these mutations
exhibit gene expression signatures that are concordant with
gene expression changes observed in samples with coding
mutations splicing factors SF3B1, FUBP1, and RBM1037. Toge-
ther these results demonstrate that rare non-coding mutations
may result in similar perturbations to both common and com-
plementary biological processes.
There are several caveats to the results reported in this study.
First, there is relatively low power to detect non-coding mutations
in the cohort, particularly in cancer types with small numbers of
Fig. 4 Pathway and network modules containing PID-C and PID-N genes. a Network of functional interactions between PID-C and PID-N genes. Nodes
represent PID-C and PID-N genes and edges show functional interactions from the ReactomeFI network (gray), physical protein–protein interactions from
the BioGRID network (blue), or interactions recorded in both networks (purple). Node color indicates PID-C genes (green), PID-N genes (yellow), or both
PID-C and PID-N genes (orange); node size is proportional to the score of the gene; and the pie chart diagram in each node represents the relative
proportions of coding and non-coding mutations associated with the corresponding gene. Dotted outlines indicate clusters of genes with roles in chromatin
organization and cell proliferation, which predominantly contain PID-C genes; development, which includes comparable amounts of PID-C and PID-N
genes; and RNA splicing, which contains PID-N genes. A core cluster of genes with many known drivers is also indicated. b Pathway modules containing
PID-C and PID-N genes. Each row in the matrix corresponds to a PID-C or PID-N gene, and each column in the matrix corresponds to a pathway module
enriched in PID-C and/or PID-N genes (see the Methods section). A ﬁlled entry indicates a gene (row) that belongs to one or more pathways (column)
colored according to gene membership in PID-C genes (green), PID-N genes (yellow), or both PID-C and PID-N genes (orange). A dark colored entry
indicates that a PID-C or PID-N gene belongs to a pathway that is signiﬁcantly enriched for PID-C or PID-N genes, respectively. A lightly colored entry
indicates that a PID-C or PID-N gene belongs to a pathway that is signiﬁcantly enriched for the union of PID-C and PID-N genes, but not for PID-C or PID-N
genes separately. Enrichments are summarized by circles adjacent each pathway module name and PID gene name. Boxed circles indicate that a pathway
module contains a pathway that is signiﬁcantly more enriched for the union of the PID-C and PID-N genes than the PID-C and PID-N results separately. The
enriched modules and PID genes are clustered into four biological processes: chromatin, development, proliferation, and RNA splicing as indicated.
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patients. Second, transcriptomic data were available for only a
subset of samples, further reducing our ability to validate our
predictions using gene expression data. Third, our pathway and
network analysis relied on the driver p-values from the PCAWG
Drivers and Functional Interpretation Working Group analysis16.
While this analysis accounts for regional variations in the back-
ground mutation rate across the genome, it is possible that these
corrections are incomplete. Furthermore, if the uncorrected
confounding variables are correlated with gene membership in
pathways and subnetworks, then the false positive rates in our
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analysis may be higher than estimated. All of these factors, plus
other unknown confounding variables, make it difﬁcult to assess
the false discovery rate of our predictions, particularly for PID-N
genes. Further experimental validation of these predictions is
necessary to determine the true positives from false positives in
our PID gene lists.
Because of limited power in individual cancer types, our
pathway and network analysis focused on associations found
across cancer and tissue types. Thus, we primarily utilized gen-
eric, tissue-independent network and pathway information.
However, it is well known that gene–gene interactions vary across
tissues and that cancer cells rewire signaling and regulatory net-
works. Future investigations that consider the variable landscape
of regulatory and physical interactions across tissues may offer a
new perspective on the data. Speciﬁcally, each cell type has a
different epigenetic wiring and regulatory machinery, and non-
coding mutations may target cell type-dependent vulnerabilities.
Approaches that incorporate tissue-speciﬁc, cancer-speciﬁc, or
patient-speciﬁc gene–gene regulatory information may reveal new
classes of drivers unexplored with our current approaches.
Our pathway- and network-driven strategies enable us to
interpret the coding and non-coding landscape of tumor genomes
to discover driver mechanisms in interconnected systems of
genes. This approach has multiple beneﬁts. First, by broadening
our mutation analysis from single genomic elements to pathways
and networks of multiple genes, we identify new components of
known cancer pathways that are recurrently altered by both
coding and non-coding mutations, and thus likely to be impor-
tant in cancer. Second, we identify new pathways and subnet-
works that would remain unseen in an analysis focusing on
coding sequences. Investigation of the coding and non-coding
mutations that perturb these pathways and networks will enable
more accurate patient-stratiﬁcation strategies, pathway-focused
biomarkers, and therapeutic approaches.
Methods
Mutation and pathway data. We used gene scores derived from the PCAWG
Drivers and Functional Interpretation Working Group analysis16 and combined
several pathways and interaction networks for our pathway and network analyses.
Here, we use the term “pathway methods” to refer to approaches that utilize sets of
related genes for their analysis and use the term “network methods” to refer to
approaches that utilize pairwise interactions among genes and/or their products.
Somatic mutation data. We obtained consensus driver p-values (syn8494939)
from the PCAWG Drivers and Functional Interpretation Working Group analy-
sis16 for coding and non-coding (core promoter, 5′ UTR, 3′ UTR, enhancers)
genomic elements for the Pancan-no-skin–melanoma–lymph cohort. We removed
driver p-values for several elements (H3F3A and HIST1H4D coding; LEPROTL1,
TBC1D12, and WDR74 5′ UTR; and chr6:142705600-142706400 enhancer, which
targets ADGRG6) that the PCAWG Drivers and Functional Interpretation
Working Group analysis had manually examined and discarded. We included
enhancers with ≤ 5 gene targets (syn7201027), which covered 89% of enhancers
elements from the PCAWG Drivers and Functional Interpretation Working Group
analysis16. In cases where the PCAWG Drivers and Functional Interpretation
Working Group analysis reported multiple p-values for the same genomic element,
we used the smallest reported p-value for that element.
Derivation of gene scores. Pathway databases and gene interaction networks
typically record information at the level of individual genes. Thus, we formed
coding and non-coding gene scores by combining PCAWG driver p-values across
coding and/or non-coding (core promoter, 5′ UTR, 3′ UTR, enhancer) genomic
elements as follows. Let px(g) be the driver p-value for element x of gene g from
the PCAWG Drivers and Functional Interpretation Working Group analysis16.
We combined p-values from multiple elements using Fisher’s method, where we
selected the minimum p-value min(ppromoter(g), p5’UTR(g)) for overlapping core
promoter and 5′ UTR elements on gene g and the minimum p-value penhancer(g) of
all enhancers targeting gene g. Using this approach, we deﬁned the following gene
scores on coding (GS-C), non-coding, (GS-N), and combined coding and non-
coding (GS-CN) genomic elements:
1. GS-C: pC(g)= pcoding(g)
2. GS-N: pN(g)= ﬁsher(min(ppromoter(g), p5′UTR(g)), p3′UTR(g), penhancer(g))
3. GS-CN: pCN(g)= ﬁsher(pcoding(g), min(ppromoter(g), p5′UTR(g)), p3′UTR(g),
penhancer(g)).
Here, p ¼ fisherðp1; ¼ ; pkÞ ¼ 2
Pk
i¼1 ln pið Þ  χ22k , is Fisher’s method for
combining p-values, where 2k is the degrees of freedom in the calculation. When
the driver p-value for a genomic element was undeﬁned, we omitted that element
from the calculation and reduced the number of degrees of freedom.
For the pathway and networks methods that analyze individual mutations, we
used mutations from the PCAWG MAF (syn7364923) on the same genomic
elements as the PCAWG Drivers and Functional Interpretation Working Group
analysis, i.e., coding, core promoter, 5′ UTR, 3′ UTR, and enhancer. We removed
melanoma and lymphoma samples as well as 69 hypermutated samples with over
30 mutations/MB (syn7894281, syn7814911). We also removed mutations in
elements that the PCAWG Drivers and Functional Interpretation Working Group
analysis had manually examined and discarded (see above), resulting in lists of
mutations used for later assessing biological relevance of our results (syn8103141,
syn9684700).
Pathway and network databases. Pathway methods used gene sets from six
databases: CORUM38, GO39, InterPro40, KEGG41, NCI Nature42, and Reactome43
(syn3164548, syn11426307), where small (<3 genes) and large (>1000 genes)
pathways were removed.
Network methods used interactions from three interaction networks: the largest
connected subnetwork of the ReactomeFI 2015 interaction network44 (syn3254781)
with high-conﬁdence (≥ 0.75 conﬁdence score) interactions, which we treated as
undirected; the largest connected subnetwork of the iRefIndex14 interaction
network45, which we augmented with interactions from the KEGG pathway
database41 (syn10903761). The BioGRID interaction network46 (syn3164609) was
also used to evaluate and annotate results.
Individual pathway and network algorithms. We applied seven pathway and
network methods to the gene scores and mutation data. We used two pathway
methods: ActivePathways19 and a hypergeometric analysis (Vazquez). We also
used ﬁve network methods: CanIsoNet20, Hierarchical HotNet21, an induced
subnetwork analysis (Reyna and Raphael, in preparation), NBDI22, and SSA-ME23.
Table 1 shows pathway databases and interaction networks used by each method.
Using these pathway and network databases, we ran each method on the GS-C,
GS-N, and GS-CN gene scores to identify three corresponding lists of genes. Each
method evaluated the statistical signiﬁcance of its results on each data set.
Non-coding value-added (NCVA) procedure. The GS-CN results leverage both
coding and non-coding mutation data, improving the detection of weaker pathway
and network signals. We devised a non-coding value-added (NCVA) procedure to
separate the coding and non-coding signals in this combined analysis, resulting in a
Fig. 5 RNA splicing factors are targeted primarily by non-coding mutations and alter expression of similar pathways as coding mutations in splicing
factors. a Heatmap of Gene Set Enrichment Analysis (GSEA) Normalized Enrichment Scores (NES). The columns of the matrix indicate non-coding
mutations in splicing-related PID-N genes and coding mutations in splicing genes reported in ref. 37, and the rows of the matrix indicate 47 curated gene
sets37. Red heatmap entries represent an upregulation of the pathway in the mutated samples with respect to the non-mutated samples, and blue heatmap
entries represent a downregulation. The ﬁrst column annotation indicates mutation cluster membership according to common pathway regulation. The
second column annotation indicates whether a mutation is a non-coding mutation in a PID-N gene or a coding mutation, with the third column annotation
speciﬁes the aberration type (promoter, 5′ UTR, 3′ UTR, missense, or truncating). The fourth column annotation indicates the cancer type for coding
mutations. The mutations cluster into three groups: C1, C2, and C3. The pathways cluster into two groups: P1 and P2, where P1 contains an immune
signature gene sets and P2 contains cell-autonomous gene sets. b t-SNE plot of mutated elements. Gene expression signatures for samples with non-
coding mutations clusters in splicing-related PID-N genes with gene expression signatures for coding mutations in previously published splicing factors.
The shape of each point denotes the mutation cluster assignment (C1, C2, or C3), and the color represents whether the corresponding gene is a PID-N
gene with non-coding mutations or a splicing factor gene with coding mutations.
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set of NCVA genes for which the non-coding mutation data make a statistically
signiﬁcant contribution to their discovery in the GS-CN results. Speciﬁcally, we
evaluated the statistical signiﬁcance of genes in the GS-CN results using a per-
mutation test where the driver p-values for coding elements were ﬁxed and the
driver p-values for non-coding elements were permuted. This procedure identiﬁed
the subset of the GS-CN results that were reported infrequently (p < 0.1) on per-
muted data, and thus more likely to be true positives. Each method’s NCVA results
were added to that method’s overall set of non-coding results (GS-N).
Consensus results for pathway and network methods. We deﬁned a consensus
set of genes for each set of results: GS-C results, GS-N results, GS-CN results, and
GS-N combined with NCVA results, across our seven pathway and network
methods. Speciﬁcally, we deﬁned a gene to be a consensus gene if it was found by a
majority (≥ 4/7) of the pathway and network methods. For our analysis, we focused
on the consensus GS-C results, which we call the pathway-implicated driver genes
with coding variants (PID-C), and the consensus from the GS-N results combined
with NCVA results, which we call the pathway-implicated driver genes with non-
coding variants (PID-N). We deﬁned PID-C genes as the 87 genes in the consensus
of the GS-C results, and we deﬁned PID-N genes as the 93 genes in the consensus
of each method’s GS-N results combined with its NCVA results. We performed
several analyses to assess the biological relevance of PID-C and PID-N genes.
Identiﬁcation of mutational signatures of PID genes. We performed a
permutation-based enrichment test for mutation signatures from PCAWG muta-
tion signatures analysis47. We identiﬁed the most likely mutation signature for each
non-coding mutation in PID-N genes and compared them to randomly chosen
non-coding mutations in non-PID-N genes.
Improved network neighborhood scores of PID genes. To assess the extent to
which gene scores on PID genes contribute to their detection by pathway and
network methods, we considered the contribution of each PID gene’s score to the
score of its network neighborhood in the BioGRID interaction network.
For each PID gene g, we used Fisher’s method to combine the gene scores of the
ﬁrst-order network neighbors of g both with and without the score of g itself. In
particular, for gene g, let p(g) be the gene score for g and N(g) be the network
neighborhood of g. Then
pwithNðgÞ ¼ fisher pðvÞ : v 2 N gð Þ∪ gf gð Þ
is a score for the network neighborhood of g when including gene g and
pwithoutNðgÞ ¼ fisher pðvÞ : v 2 N gð Þð Þ
is a score for the network neighborhood of g when excluding gene g.
If the network neighborhood of g has a smaller p-value with g than without g,
i.e., pwithNðgÞ < p
without
NðgÞ , then gene g improves the score of the network neighborhood,
suggesting that the gene score of g plays a role in its detection by pathway and
network methods. Alternatively, if the network neighborhood of g has a larger
p-value with g than without g, i.e., pwithNðgÞ > p
without
NðgÞ , then gene g worsens the score of
the network neighborhood, suggesting that the gene scores of the network
neighbors of g are predominantly responsible for the detection of g by pathway and
network methods.
We performed this test for every PID-C gene with GS-C gene scores and every
PID-N gene with GS-N gene scores. We also sampled genes uniformly at random
from the network (87 for PID-C genes and 93 for PID-N genes; 106 trials) to
ascertain whether signiﬁcantly more PID genes that improved the scores of their
network neighborhoods than expected by chance.
Expression analysis of PID genes. We evaluated whether mutation status of each
PID gene was correlated with RNA expression. We used PCAWG-3 gene
expression data (syn5553991), which was averaged from TopHat2 and STAR-based
alignments, with FPKM-UQ normalization. Tumor type and copy-number aber-
rations are known to be covariates for gene expression, so we conditioned on tumor
types and annotated copy-number aberrations.
We used the following procedure to assess expression correlations on individual
tumor types. We only considered cases with at least three mutated samples and
three non-mutated samples to restrict our analysis to cases with sufﬁcient statistical
power. For each PID-C gene or each non-coding element in a PID-N gene, we
partitioned the samples with expression data into a set A of samples with mutation
(s) in the element and a set B of samples without mutations in the element. We
performed the Wilcoxon rank-sum test for the expression of the gene in sets A and
B and performed the Benjamini–Hochberg correction on each coding or non-
coding element to provide FDRs.
We used the following procedure to assess expression correlations across tumor
types. We only considered cases with at least one mutated sample and one non-
mutated sample to restrict our analysis to cases with sufﬁcient statistical power. For
each PID-C gene and each non-coding element in a PID-N gene, we partitioned
the samples with expression data into sets Ac of samples in cohort c with mutation
(s) in the element and sets Bc of samples in cohort c without mutations in the
element. We converted the expression values into z-scores using the expression
from non-mutated samples in cohort c, and we computed the Wilcoxon rank-sum
test on the expression of the gene in sets from A=⋃c∊C Ac and B=⋃c∊C Bc, where
C is the set of all cohorts containing samples with mutation(s) in the element. We
then performed the Benjamini–Hochberg correction on each coding or non-coding
element to provide FDRs.
Network annotation of PID genes. We performed a permutation test to evaluate
the statistical signiﬁcance of the number of interactions in the BioGRID high-
conﬁdence interaction network between PID-C genes, the number of interactions
between PID-N genes, and the number of interactions between PID-C and PID-N
genes, i.e., when a PID-C gene interacts with a PID-N gene. To compute the
permutation p-value, we sampled random networks uniformly at random from the
collection of networks with the same degree sequence as the BioGRID network.
We found connected subnetworks of 46 PID-C genes (31 genes expected,
p= 9 × 10−4) and 16 PID-N genes (10 genes expected, p= 6.1 × 10−2) in the high-
conﬁdence BioGRID48 protein–protein interaction (PPI) network. The union of
the PID-C and PID-N genes formed a larger connected subnetwork of 73 genes
(Fig. 4a). These connected subnetworks were signiﬁcantly larger than expected
by chance according to this permutation test (57 genes expected, p= 2.2 × 10−3).
Furthermore, we observed statistically signiﬁcant numbers of protein–protein
interactions between PID-C and PID-N genes (67 interactions observed vs. 45
expected, p= 6 × 10−4), suggesting that the associated mutations may target an
overlapping set of underlying pathways. The PID-C genes were connected by
signiﬁcantly more interactions than expected (64 vs. 40 expected, p < 10−4), and the
PID-N genes were interconnected at a sub-signiﬁcant level (18 vs 12 expected,
p= 6.8 × 10−2). Thus, certain pathways are affected by either coding or non-coding
mutations, but some pathways are affected by a complement of both coding and
non-coding mutations.
Pathway annotation of PID genes. Using g:Proﬁler34, we performed a pathway
enrichment analysis for PID genes and 12,061 gene sets representing GO biological
processes and Reactome pathways. We used the Benjamini–Hochberg correction to
control the FDR of the results.
Characterization of PID genes in RNA splicing. GSEA enrichment analysis was
performed with the default parameters using the curated pathway gene lists37 for
samples harboring non-synonymous coding mutations in ﬁve genes (FUBP1,
RBM10, SF3B1, SRSF2, and U2AF1) with conﬁrmed on-target splicing deregula-
tion. Due to limited number of samples with RNA-seq data in individual tumor
types, we restricted our analysis to missense mutations in SF3B1, truncating
mutations in RBM10, and truncating mutations in FUBP1 for tumor types con-
tained at least three samples with these classes of mutations. Each tumor type
containing such mutations was considered separately37.
We performed the same GSEA analysis for non-coding mutations in 17 PID-N
genes that were annotated as involved in RNA splicing. Due to limited number of
samples from individual tumor types containing mutations in these genes (often
there was only one per tumor type), we performed GSEA analysis jointly on all
tumor types containing mutations in an individual PID-N gene, restricting the
non-mutated group to samples from the same tumor types as the mutant samples.
The GSEA Normalized Enrichment Scores (NES) were clustered using hierarchical
complete linkage clustering on the Euclidean distance between the NES scores.
Separately, we computed a 2D projection of NES scores using t-Distributed
Stochastic Neighbor Embedding (t-SNE).
Ethical review. Sequencing of human subjects' tissue was performed by ICGC and
TCGA consortium members under approval of local Institutional Review Boards
(IRBs). Informed consent was obtained from all human participants. All data were
deidentiﬁed for this study, and data access for participating researchers was
obtained through data access agreements between local institutions, the ICGC Data
Access Compliance Ofﬁce (DACO), and the NIH dbGaP.
Table 1 Summary of pathway database and interaction
network data for each method.
Method Pathway databases or interaction networks
ActivePathways Gene Ontology (GO)39 biological processes,
Reactome43 pathways
CanIsoNet STRING v1050, DIMA51, 3did52
Hierarchical HotNet ReactomeFI 201543, iRefIndex14+KEGG41, 45
Hypergeometric
analysis
GO biological processes; CORUM38, KEGG41,
InterPro41, Nature NCI42 pathways
Induced subnetwork
analysis
ReactomeFI 201543, iRefIndex14+KEGG41, 45
NBDI ReactomeFI 201543
SSA-ME ReactomeFI 201543
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Data availability
Raw data are available through the PCAWG data portal https://dcc.icgc.org/pcawg.
Processed data from the PCAWG Networks and Pathways working groups as well as
other PCAWG working groups are available on www.synapse.org at the Synapse links
provided in this section. The source data underlying Figs. 2a–c, 3a, b, c, and
Supplementary Figs. 1a–c, 7a–c, 10a–h are provided as a Source Data ﬁle. Somatic and
germline variant calls, mutational signatures, subclonal reconstructions, transcript
abundance, splice calls and other core data generated by the ICGC/TCGA Pan-cancer
Analysis of Whole Genomes Consortium is described here15 and available for download
at https://dcc.icgc.org/releases/PCAWG. Additional information on accessing the data,
including raw read ﬁles, can be found at https://docs.icgc.org/pcawg/data/. In accordance
with the data access policies of the ICGC and TCGA projects, most molecular, clinical
and specimen data are in an open tier, which does not require access approval. To access
potentially identiﬁcation information, such as germline alleles and underlying sequencing
data, researchers will need to apply to the TCGA Data Access Committee (DAC) via
dbGaP (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA
portion of the data set, and to the ICGC Data Access Compliance Ofﬁce (DACO; http://
icgc.org/daco) for the ICGC portion. In addition, to access somatic single-nucleotide
variants derived from TCGA donors, researchers will also need to obtain dbGaP
authorization.
Derived data sets described speciﬁcally in this paper can be found at these locations:
Label Synapse ID ICGC DCC URL ICGC DCC ﬁle name Access
(open/controlled)
PCAWG driver p-values syn8494939 https://dcc.icgc.org/releases/PCAWG/
networks/
ﬁnal_integration_results_
2017_03_16.tar.gz
Open
Enhancer-gene mappings syn7201027 https://dcc.icgc.org/releases/PCAWG/
networks/
map.enhancer.gene.txt.gz Open
Somatic MAF ﬁle syn7364923 https://dcc.icgc.org/releases/PCAWG/
consensus_snv_indel/
ﬁnal_consensus_passonly.snv_mnv_
indel.icgc.public.maf.gz
Open
Somatic MAF ﬁle syn7364923 https://dcc.icgc.org/releases/PCAWG/
consensus_snv_indel/
ﬁnal_consensus_passonly.snv_mnv_
indel.tcga.controlled.maf.gz
Controlled
Hypermutated donors syn7894281 https://dcc.icgc.org/releases/PCAWG/
networks/
Hypermutated_spls_removed_
ActiveDriver2_AllScores_211216.txt
Open
Hypermutated samples syn7814911 https://dcc.icgc.org/releases/PCAWG/
networks/
Hypermutated_spls_removed_
ActiveDriver2_AllScores_291116.aliquotid.txt
Open
Mutations to coding and
noncoding elements
syn8103141 https://dcc.icgc.org/releases/PCAWG/
networks/
PCAWG_mutations_to_
elements.icgc.public.txt.gz
Open
Mutations to coding and
noncoding elements
syn8103141 https://dcc.icgc.org/releases/PCAWG/
networks/
PCAWG_mutations_to_
elements.tcga.controlled.txt.gz
Controlled
Mutation matrix syn9684700 https://dcc.icgc.org/releases/PCAWG/
networks/
PCAWG.gene_
status.all.tsv.gz
Controlled
Primary pathway databases syn3164548 https://dcc.icgc.org/releases/PCAWG/
networks/
Gene_sets_pathways_
processes_functions.zip
Open
Secondary pathway databases syn11426307 https://dcc.icgc.org/releases/PCAWG/
networks/
PCAWG-5.pathway.data.
CNIO.tar.gz
Open
ReactomeFI 2015 network syn3254781 https://dcc.icgc.org/releases/PCAWG/
networks/
Functional_interaction_network_
Reactome_FI_Network_2015.zip
Open
iRefIndex14 network syn10903761 https://dcc.icgc.org/releases/PCAWG/
networks/
ireﬁndex14-kegg.tsv.gz Open
BioGRID network syn3164609 https://dcc.icgc.org/releases/PCAWG/
networks/
Protein_Protein_interaction_
network_BIOGRID_ﬁltered.zip
Open
STRING v10 network syn11712027 https://dcc.icgc.org/releases/PCAWG/
networks/
string10_ppi_high_
conﬁdent_edges.tsv
Open
PCAWG gene
expression data
syn5553991 https://dcc.icgc.org/releases/PCAWG/
transcriptome/gene_expression/
tophat_star_fpkm_uq.v2_
aliquot_gl.tsv.gz
Controlled
PCAWG pathway and
network method results
syn21413360 https://dcc.icgc.org/releases/PCAWG/
networks/
pathway_and_network_
method_results.tar.gz
Open
PCAWG pathway and
network consensus results
syn11654843 https://dcc.icgc.org/releases/PCAWG/
networks/
method_results_2017_
10_10.tar.gz
Open
Coding and noncoding
elements
syn21416282 https://dcc.icgc.org/releases/PCAWG/
networks/
gene-coding-and-non-
coding-elements.tar.gz
Open
Transcript expression data
(Counts)
syn7536588 https://dcc.icgc.org/releases/PCAWG/
transcriptome/transcript_expression/
pcawg.rnaseq.transcript.
expr.counts.tsv.gz
Controlled
Transcript expression
data (FPKM)
syn7536589 https://dcc.icgc.org/releases/PCAWG/
transcriptome/transcript_expression/
pcawg.rnaseq.transcript.
expr.fpkm.tsv.gz
Controlled
eQTL data syn17096221 https://dcc.icgc.org/releases/PCAWG/
transcriptome/eQTL/summarystats/
somatic/
all_somatic_eqtl.
tsv.tar.gz
Controlled
Gene-level copy-number data syn8291899 https://dcc.icgc.org/releases/PCAWG/
consensus_cnv/gene_level_calls/
all_samples.consensus_
CN.by_gene.170214.txt.gz
Open
CanIsoNet PCAWG Ensembl
transcripts
syn7536587 https://dcc.icgc.org/releases/PCAWG/
transcriptome/transcript_expression/
pcawg.rnaseq.transcript.
expr.tpm.tsv.gz
Open
CanIsoNet GTEx Ensembl
transcripts
syn7596599 https://dcc.icgc.org/releases/PCAWG/
transcriptome/transcript_expression/
GTEX_v4.pcawg.transcripts.
tpm.tsv.gz
Open
CanIsoNet ﬁltered PCAWG
samples
syn7416381 https://dcc.icgc.org/releases/PCAWG/
transcriptome/metadata/
rnaseq.extended.metadata.
aliquot_id.V4.tsv
Open
CanIsoNet ﬁltered GTEx
samples
syn7596611 https://dcc.icgc.org/releases/PCAWG/
transcriptome/metadata/
GTEX_v4.metadata.
tsv.gz
Open
CanIsoNet protein–protein
isoforms
syn10245952 https://dcc.icgc.org/releases/PCAWG/
networks/
isoNet.tsv.gz Open
CanIsoNet shortest path
results
syn9770515 https://dcc.icgc.org/releases/PCAWG/
networks/
string_cosmic_neighbourhood_
min900_shell3_20160527.tsv.xz
Open
CanIsoNet functional regions syn7345646 https://dcc.icgc.org/releases/PCAWG/
networks/
allCombined.zip Open
CanIsoNet results (noncoding
region)
syn9765614 CanIsoNet results (noncoding region) non_canIsoNet_mdi_results_
noLymNoMel.tsv
Open
CanIsoNet results (coding
region)
syn9765615 CanIsoNet results (coding region) cds_canIsoNet_mdi_
results_noLymNoMel.tsv
Open
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Code availability
Code for the contributing methods in this analysis can be found from their respective
papers or by request to the contributing author. The core computational pipelines used
by the PCAWG Consortium for alignment, quality control and variant calling are
available to the public at https://dockstore.org/search?search=pcawg under the GNU
General Public License v3.0, which allows for reuse and distribution.
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